2-三氟甲基-4-氨基喹啉 | 1700-93-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2-三氟甲基-4-氨基喹啉
• 英文名称: 4-Amino-2-trifluormethyl-chinolin
• 英文别名: 4-amino-2-trifluoromethyl-quinoline；2-trifluoromethyl-quinolin-4-ylamine；2-(Trifluoromethyl)quinolin-4-amine
• CAS: 1700-93-2
• 化学式: C₁₀H₇F₃N₂
• 分子量: 212.174
• InChiKey: LDALBEJGMLUINP-UHFFFAOYSA-N

物化性质

• 熔点：
  138-140 °C
• 沸点：
  308.8±42.0 °C(Predicted)
• 密度：
  1.390±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2-8°C，避光保存，需在惰性气体环境中保存。

反应信息

• 作为反应物：
  描述：

  对甲氧基苯异氰酸酯 、 2-三氟甲基-4-氨基喹啉 在 sodium t-butanolate 作用下， 以 二甲基亚砜 为溶剂， 反应 0.5h， 以80%的产率得到1-(2-Chloroquinolin-4-yl)-3-(3-(pyrimidin-2-yl)phenyl)urea
  参考文献：
  名称：

  Synthesis of aryl-heteroaryl ureas (AHUs) based on 4-aminoquinoline and their evaluation against the insulin-like growth factor receptor (IGF-1R)

  摘要：

  The insulin-like growth factor receptor (IGF-1R) is a receptor tyrosine kinase (RTK) involved in all stages of the development and propagation of breast and other cancers. The inhibition of IGF-1R by small molecules remains a promising strategy to treat cancer. Herein, we explore SAR around previously characterized lead compound (1), which is an aryl-heteroaryl urea (AHU) consisting of 4-aminoquinaldine and a substituted aromatic ring system. A library of novel AHU compounds was prepared based on derivatives of the 4-aminoquinoline heterocycle (including various 2-substituted derivatives, and naphthyridines). The compounds were screened for in vitro inhibitory activity against IGF-1R, and several compounds with improved activity (3-5 mu M) were identified. Furthermore, a computational docking study was performed, which identifies a fairly consistent lowest energy mode of binding for the more-active set of inhibitors in this series, while the less-active inhibitors do not adopt a consistent mode of binding. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.06.071
• 作为产物：
  描述：

  4-叠氮基-2-(三氟甲基)喹啉 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以73%的产率得到2-三氟甲基-4-氨基喹啉
  参考文献：
  名称：

  Synthesis of aryl-heteroaryl ureas (AHUs) based on 4-aminoquinoline and their evaluation against the insulin-like growth factor receptor (IGF-1R)

  摘要：

  The insulin-like growth factor receptor (IGF-1R) is a receptor tyrosine kinase (RTK) involved in all stages of the development and propagation of breast and other cancers. The inhibition of IGF-1R by small molecules remains a promising strategy to treat cancer. Herein, we explore SAR around previously characterized lead compound (1), which is an aryl-heteroaryl urea (AHU) consisting of 4-aminoquinaldine and a substituted aromatic ring system. A library of novel AHU compounds was prepared based on derivatives of the 4-aminoquinoline heterocycle (including various 2-substituted derivatives, and naphthyridines). The compounds were screened for in vitro inhibitory activity against IGF-1R, and several compounds with improved activity (3-5 mu M) were identified. Furthermore, a computational docking study was performed, which identifies a fairly consistent lowest energy mode of binding for the more-active set of inhibitors in this series, while the less-active inhibitors do not adopt a consistent mode of binding. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.06.071

文献信息

• Basic antiinflammatory compounds. N,N',N''-Trisubstituted guanidines
  作者：Schneur Rachlin、E. Bramm、I. Ahnfelt-Roenne、E. Arrigoni-Martelli

  DOI：10.1021/jm00175a004

  日期：1980.1

  A variety of basic N,N',N'',-trisubstituted guanidines was prepared and tested for antiinflammatory activity. Compounds with a thiazolylguanidine moiety linked to the 4 position of the 2-methylquinoline ring exhibited fairly high antiinflammatory activity. Optimal activity was associated with the presence of N-cycloalkyl substituents on N''-4-(2-methylquinolyl)-N'-2-thiazolylguanidine. Pharmacological

  制备了多种碱性的N，N′，N″，三取代的胍，并测试了其抗炎活性。具有连接至2-甲基喹啉环的4位的噻唑基胍部分的化合物表现出相当高的抗炎活性。最佳活性与N′-4-（2-甲基喹啉基）-N′-2-噻唑基胍上N-环烷基取代基的存在有关。介绍并讨论了有关N-环己基-N''-4-（2-甲基喹啉基）-N'-2-噻唑基胍（SR 1368，44）的药理数据。
• [EN] MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND THEIR USE<br/>[FR] MODULATEURS DU RÉCEPTEUR X2 DE LA PROTÉINE G LIÉE AU MAS ET PRODUITS APPARENTÉS ET LEUR UTILISATION
  申请人：ESCIENT PHARMACEUTICALS INC

  公开号：WO2022087083A1

  公开（公告）日：2022-04-28

  Methods are provided for modulating MRGPRX2 or a MRGPRX2 ortholog generally, or for treating a MRGPRX2 or a MRGPRX2 ortholog dependent condition more specifically, by contacting the MRGPRX2 or the MRGPRX2 ortholog by administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein W, Z, R1, R2, R3, R4, R5, R6and Rxare as defined herein. Pharmaceutical compositions containing such compounds, as well as the compounds themselves, are also provided.

  本发明提供了调节MRGPRX2或MRGPRX2同源物的方法，或更具体地治疗MRGPRX2或MRGPRX2同源物依赖性疾病的方法，通过向需要的受体中注射具有结构（I）的化合物或其药学上可接受的盐、异构体、水合物、溶剂化物或同位素的有效剂量，其中W、Z、R1、R2、R3、R4、R5、R6和Rx的定义如本文所述。本发明还提供了包含这些化合物的制药组合物，以及这些化合物本身。
• HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS
  申请人：ABBVIE DEUTSCHLAND GMBH & CO. KG

  公开号：US20140148458A1

  公开（公告）日：2014-05-29

  The present invention relates to a heterocyclic compound of the general formula (I) and their use and preparation, methods of making the compounds, compositions containing at least one of said compounds, and methods of treatment using at least one compound. In particular, compounds of the general formula (I) are useful for inhibiting glycogen synthase kinase 3 (GSK-3),

  本发明涉及一种一般式（I）的杂环化合物及其使用和制备、制备该化合物的方法、含有至少一种该化合物的组合物以及使用至少一种该化合物的治疗方法。特别地，一般式（I）的化合物对于抑制糖原合酶激酶3（GSK-3）是有用的。
• Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
  申请人：Abbott GmbH & Co. KG

  公开号：EP2535336A1

  公开（公告）日：2012-12-19

  The present invention relates to a heterocyclic compound of the general formula (I) and their use and preparation, methods of making the compounds, compositions containing at least one of said compounds, and methods of treatment using at least one compound. In particular, compounds of the general formula (I) are useful for inhibiting glycogen synthase kinase 3 (GSK-3),

  本发明涉及通式（I）的杂环化合物 及其用途和制备方法、化合物的制造方法、含有至少一种所述化合物的组合物以及使用至少一种化合物进行治疗的方法。通式（I）化合物尤其适用于抑制糖原合酶激酶 3（GSK-3）、
• WO2008/46919
  申请人：——

  公开号：——

  公开（公告）日：——